These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10410761)

  • 1. COMT inhibition with entacapone in the treatment of Parkinson's disease.
    Rinne UK; Gordin A; Teräväinen HT
    Adv Neurol; 1999; 80():491-4. PubMed ID: 10410761
    [No Abstract]   [Full Text] [Related]  

  • 2. [Entacapone in the therapy of Parkinson disease].
    Teräväinen H
    Duodecim; 1999; 115(24):2734-44. PubMed ID: 11979613
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [COMT inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553
    [No Abstract]   [Full Text] [Related]  

  • 5. COMT inhibition and safety.
    Martignoni E; Blandini F; Pacchetti C; Nappi G
    Funct Neurol; 2001; 16(4 Suppl):135-40. PubMed ID: 11996508
    [No Abstract]   [Full Text] [Related]  

  • 6. Entacapone in the management of Parkinson's disease.
    Henchcliffe C; Waters C
    Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopaminergic therapy in Parkinson disease: time to stride back?
    Stoessl AJ
    Ann Neurol; 2010 Jul; 68(1):3-5. PubMed ID: 20583222
    [No Abstract]   [Full Text] [Related]  

  • 8. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entacapone for Parkinson's disease.
    Med Lett Drugs Ther; 2000 Jan; 42(1070):7-8. PubMed ID: 10696231
    [No Abstract]   [Full Text] [Related]  

  • 11. COMT inhibition in Parkinson's disease: rationale and clinical relevance.
    Deleu D
    Acta Neurol Belg; 2000 Mar; 100(1):5-7. PubMed ID: 10779856
    [No Abstract]   [Full Text] [Related]  

  • 12. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract]   [Full Text] [Related]  

  • 14. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
    Lee MS; Kim HS; Cho EK; Lim JH; Rinne JO
    Neurology; 2002 Feb; 58(4):564-7. PubMed ID: 11865133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment in Parkinson disease].
    Takáts A
    Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.
    Kurkela M; Siiskonen A; Finel M; Tammela P; Taskinen J; Vuorela P
    Anal Biochem; 2004 Aug; 331(1):198-200. PubMed ID: 15246016
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Parkinson's disease with COMT inhibitors].
    Shabtai H; Korczyn A
    Harefuah; 2001 Oct; 140(10):935-7. PubMed ID: 11681127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.